|
![]() |
|
|
Methylprednisolone
drug data and news
Methylprednisolone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Methylprednisolone | ||
| Brand Names/Synonyms | 6.Alpha.-Methylprednisolone; 6alpha-Methylprednisolone; A-Methapred; Artisone-Wyeth; BRN 2340300; Besonia; Cortalone; DRG-0050; Delta-Cortef; Depo-Medrol; Dopomedrol; Esametone; Fernisolone-P; Firmacort; HSDB 3127; Lemod; M-Predrol; MEPRDL; Medesone; Medixon; Medlone 21; Medrate; Medrol; Medrol Acetate; Medrol Adt Pak; Medrol Dosepak; Medrone; Mesopren; Metastab; Methyleneprednisolone; Methylprednisolon; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Sodium Succinate; Methylprednisolone, Pharma; Methylprednisolonum [Inn-Latin]; Meti-Derm; Metilbetasone; Metilprednisolona [Inn-Spanish]; Metilprednisolone [Dcit]; Metrisone; Metrocort; Metysolon; Moderin; NSC-19987; Nirypan; Noretona; Predni N Tablinen; Prednisolone; Prednisolone, Methyl-; Prednol- L; Prelone; Promacortine; Reactenol; Sieropresol; Solomet; Solu-Medrol; Sterane; Summicort;; Suprametil; U 7532; Urbason; Urbasone; Wyacort | ||
| Indication | Adjunctive therapy for short-term administration in rheumatoid arthritis. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Methylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents. | ||
| Mechanism Of Action | Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. | ||
| Methylprednisolone News (When available) |
Methylprednisolone Reduces Pain, Emesis, and Fatigue After Breast ... Feb 14, 2006 Study: Steroid dose doesn't stop pain Feb 15, 2006 Intravenous Steroids of Little Help in Acute Sciatica Feb 15, 2006 FDA Approves EMEND(R) (aprepitant), in Combination with Other ... Jan 11, 2006 Epidural Won't Lessen Long-Term Shingles Pain Jan 19, 2006 Shingles, Epidural Injection Does Not Reduce Long-term Pain Jan 22, 2006 Epidural Steroid Injection Not Useful for Chronic Shingles Pain Jan 19, 2006 Injection Doesn't end Shingles Pain Jan 19, 2006 Modified reperfusion in clinical lung transplantation: The results ... Jan 23, 2006 Joint Injections: A Good Idea? 12 Dec 2005 Laurels and darts Nov 17, 2005 Rash effected by stressful incident Nov 8, 2005 Iaquinta is axed in contract row Sep 21, 2005 Zanchi fails doping test Sep 21, 2005 Disease Course of Rheumatoid Arthritis Becoming Milder Sep 6, 2005 Investigational Agent Bolsters Kidney Graft Survival and Function Aug 25, 2005 Step-by-Step Plan for an Asthma Attack: New Report From Harvard ... Aug 18, 2005 Docs Predict Which Patients Will Respond to Plasma Exchange for MS Aug 12, 2005 California Institute for Regenerative Medicine Press Release: ICOC ... Aug 12, 2005 Reflex Sympathetic Dystrophy Aug 19, 2005 Seizures After a Bier Block with Clonidine and Lidocaine: Is ... Aug 22, 2005 Joint Disease Aug 16, 2005 FAMILY DOCTOR: Damage to optic nerve is rarely reversible Jul 27, 2005 Travel-Associated Dengue Infections—United States, 2001-2004 Jul 26, 2005 Severe Protein Losing Enteropathy With Intractable Diarrhea Due to ... Jul 14, 2005 AAEP Convention 2004 Wrap-Up: Therapeutic Options Jul 26, 2005 The effects of steroids on the occurrence of postoperative atrial ... Jul 12, 2005 Neuroscientist/activist tackles current i Jun 28, 2005 Use of Rituximab in Two Unusual Antibody-Mediated Autoimmune ... Jun 22, 2005 | ||
| Dosage Forms | Tablets, Suspension | ||
| Drug_Category | Neuroprotective Agents; Glucocorticoids; Antiemetics; Anti-inflammatory Agents; Adrenergic Agents; ATC:D07AA01; ATC:D07AC14; ATC:D10AA02; ATC:H02AB04 | ||
| Absorption | Oral bioavailability 80-99% | ||
| Interactions |
Interactions for Methylprednisolone: The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity. Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect. | ||
| Toxicity | LD50=2000 mg/kg(orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one | ||
| Chemical Formula | C22H30O5 | ||
| Molecular Weight | 374.471 g/mol | ||
| Smiles String | CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O | ||
| Melting Point | 232.5 °C | ||
| Water Solubility | 120 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 2.134 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 1-3 hours | ||
| Protein Binding [%] | 78% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Methylprednisolone.html http://www.rxlist.com/cgi/generic/methprd.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00342 | ||
| CAS Registry Number | 83-43-2 | ||
| KEGG Compound ID | C07197 | ||
| PubChem ID | SID:149724 | ||
| PharmGKB ID | PA450466 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2245406 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |